References
- Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–27.
- Brown RP, Delp MD, Lindstedt SL, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Indust Health 13:407–84.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
- Gersh BJ, Maron BJ, Bonow RO, et al. (2011). 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:e783–831.
- Green EM, Wakimoto H, Anderson RL, et al. (2016). A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351:617–21.
- Hershberger RE, Cowan J, Morales A, Siegfried JD. (2009). Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2:253–61.
- Mahmood I, Balian JD. (1996). Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579–85.
- Mao J, Martin I, McLeod J, et al. (2017). Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. Drug Metab Rev 49:18–34.
- Marino AM, Yarde M, Patel H, et al. (2005). Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int J Pharm 297:235–41.
- Maron BJ. (2002). Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–20.
- Maron BJ, Gardin JM, Flack JM, et al. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–89.
- McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–79.
- Nagilla R, Ward KW. (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 93:2522–34.
- Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–59.
- Poirier A, Lavé T, Portmann R, et al. (2008). Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos 36:2434–44.
- Semsarian C, Ingles J, Maron MS, Maron BJ. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249–54.
- Smith DA, Beaumont K, Maurer TS, Di L. (2018). Relevance of half-life in drug design. J Med Chem 61:4273–82.
- Tang H, Mayersohn M. (2005). A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 33:1294–96.
- Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60.
- Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 32:612–19.
- Yu S, Li S, Yang H, et al. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250–54.